

(b) contacting the biological sample with an oligonucleotide that hybridizes to a sequence set forth in SEQ ID NO:1797, or a complement thereof, under moderately stringent conditions;

A1  
Cond (c) detecting in the sample an amount of an expressed polynucleotide that hybridizes to the oligonucleotide; and

(d) comparing the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence of the cancer in the patient.

---

Please add new claims 19-24 to read as follows:

---

19. (New) A method for monitoring the progression of a lung cancer in a patient, comprising the steps of:

A2 (a) contacting a biological sample obtained from the patient with an oligonucleotide that hybridizes to a sequence set forth in SEQ ID NO:1797, or a complement thereof, under moderately stringent conditions;

(b) detecting in the sample an amount of an expressed polynucleotide that hybridizes to the oligonucleotide;

(c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and

(d) comparing the amount of expressed polynucleotide detected in step (c) to the amount detected in step (b), and therefrom monitoring the progression of the cancer in the patient.

20. (New) A method for determining the presence of a lung cancer in a patient comprising:

(a) obtaining a biological sample from the patient;

(b) contacting the sample with at least two oligonucleotide primers in a reverse transcription polymerase chain reaction, wherein said oligonucleotide primers are effective for amplifying a polynucleotide sequence of SEQ ID NO:1797;

(c) detecting in the sample an amount of amplified polynucleotide sequence;  
and

(d) comparing the amount of amplified polynucleotide to a control value, and  
therefrom determining the presence of the cancer in the patient.

A2  
concl  
21. (New) The method of claim 20, wherein the oligonucleotide primers  
comprise at least 10 contiguous nucleotides of SEQ ID NO:1797.

22. (New) The method of claim 14, wherein the biological sample is selected  
from the group consisting of: lung tissue, blood, sera, sputum, urine, and a tumor biopsy.

23. (New) The method of claim 18, wherein the biological sample is selected  
from the group consisting of: lung tissue, blood, sera, sputum, urine, and a tumor biopsy.

24. (New) The method of claim 20, wherein the biological sample is selected  
from the group consisting of: lung tissue, blood, sera, sputum, urine, and a tumor biopsy.

---

#### REMARKS

In response to the Restriction Requirement dated July 23, 2002, claim 14 has been  
elected. Independent claims 19 and 20 were added to more clearly describe certain embodiments  
of the elected invention. Dependent claims 21-24 were added to recite specific embodiments of  
the elected invention. It is urged that support for the amendments may be found throughout the  
specification as originally filed, and, therefore, the amendments do not constitute new matter.  
Specific support for claim 19 may be found, for example, on page 151, line 22, to page 152, line  
2, and support for claims 20 and 21 may be found, for example, on page 150, line 17 to page 151,  
line 21. Support for claims 22-24 may be found, for example, on page 145, line 4.